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respectively. Cost-effectiveness ratio was $ 88.7 for oxyprogesteronicaproas and $ 
80.9 for dydrogesterone. ConClusions: Cost-effectiveness analysis shown, that 
the use of dydrogesterone is more effective and less costly for threatened abortion 
treatment in Ukraine. The results of pharmacoeconomic analysis will optimize the 
government, insurance companies and patients cost.
PIH26
Cost-effeCtIveness of Infant PneumoCoCCal vaCCInatIon In tHe 
netHerlands
Vemer P.1, Postma M.J.2
1UMC Groningen, Groningen, The Netherlands, 2University of Groningen, Groningen, The 
Netherlands
objeCtives: The Dutch National Immunization Program offers the 10-valent pneu-
mococcal conjugate vaccine (PCV10). Also licensed for use in the infant population 
is the 13-valent PCV (PCV13). To update cost-effectiveness (CE) estimates of PCV13 
over PCV10, using current epidemiological and economic data. Methods: We mod-
eled vaccinating a birth cohort with either PCV10 or PCV13 (3+1 dose schedule), and 
calculated costs and effects linked to resulting disease. We modeled invasive pneu-
mococcal disease (IPD), non-invasive pneumonia and acute otitis media, and con-
sidered death and lifetime impairments after IPD. We calculated direct effects in 
the vaccinated cohort and indirect effects –herd immunity for the vaccine-type (VT) 
serotypes and replacement for the non-VT serotypes– in the rest of the population. 
Since no price is available, we use a price difference of € 11 per dose and vary this 
price difference in sensitivity analyses. Epidemiological and economic data are taken 
as current as possible. A set of scenarios explore different assumptions, including 
different sets of epidemiological data, assumptions on vaccine efficacy and indirect 
effects. Results: Taking only direct effects into account PCV13 cannot be consid-
ered cost-effective, unless the price difference is much lower than € 11 per dose. In 
three scenarios, PCV10 dominates PCV13; in the other scenarios the ICER is between 
€ 89000 and € 153000 per QALY gained. If indirect effects are also taken into account, 
the ICER of PCV13 compared to PCV10 is below € 20,000 per QALY for all scenarios. 
Scenarios do not have a large impact on the policy decision, unless we assume extra 
efficacy of PCV10 against non-typeable Haemophilus influenzae. ConClusions: 
Replacing PCV10 with PCV13 is not likely to be cost-effective in preventing invasive 
pneumococcal disease in young children. Taking potential benefits in elderly into 
account, PCV13 is likely cost-effective. The CE of PCV13 was highly sensitive for indi-
rect effects our analysis.
PIH27
Cost-mInImIzatIon analysIs of dIenogest versus gonadotroPHIn-
releasIng Hormone analogues or dydrogesterone for 
endometrIosIs treatment In russIa
Avxentyeva M.
The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia
objeCtives: To perform pharmacoeconomic evaluation of dienogest vs gonadotro-
phin-releasing hormone analogues (GnRHa) or dydrogesterone for endometriosis in 
Russia. Methods: Literature search did not reveale clinically significant differences 
in efficacy between dienogest 2 mg and GnRHa in terms of pain reduction associ-
ated with endometriosis. There was no difference in efficacy with dydrogesterone 
60 mg once daily and placebo. Cost-minimization analysis was used to assess and 
compare drug costs of dienogest 2 mg daily, GnRHa - most often used in Russia 
including triptorelin, leuprorelin, buserelin (with obligatory application of add-back 
therapy for all three GnRHa) and dydrogesterone. Costs were calculated for a period 
of 6 months. Results: Costs of endometriosis treatment per patient per 6 months 
were 1102€ for triptorelin, 1118€ for leuprorelin, 340€ for buserelin, 369€ for dydro-
gesterone and 295€ for dienogest. Dydrogesterone is less effective and more costly 
alternative in comparison with buserelin and dienogest. Among alternatives with 
the same efficacy dienogest is the most efficient option leading to savings from 74€ 
to 823€ per patient in 6 months. ConClusions: Using dienogest for treatment of 
endometriosis in Russia is as effective as using GnRHa but can lead to considerable 
cost savings because add-back therapy is not required.
PIH28
Cost mInImIzatIon analysIs of tHe dIenogest use In PatIents wItH 
endometrIs under BrazIlIan PuBlIC and PrIvate PersPeCtIve
Ferracini M., Nakada C.P.
Bayer healthcare Brazil, São Paulo, Brazil
objeCtives: To provide the results from a cost-minimization (CM) model that com-
pares the use of dienogest with the use of GnRH antagonist (GnRHa) leuprorelin 
acetate, both for 6 months, in women with endometriosis-associated pelvic pain 
(EAPP) in Brazil. Methods: A(CM) model was developed in the form of a decision 
tree to mimic treatment sequence in Brazil. The analysis was conducted under the 
private and public payer perspectives, only direct costs were included, procedures 
and drug costs were obtain from Brazilian official databases of public and private 
health care system fees. This CM model compared different treatment pathways for 
women with EAPP and used a 50% improvement in pelvic pain as a definition of a 
treatment responder to elicit treatment duration. Treatment response assessment 
was at 12 week period. Two basic treatment pathways were defined: a two treatment 
sequence (2TS) and tree treatment sequence (3TS). The 2TS consists of: GnRHa/dien-
ogest followed by surgery. The 3TS consists of: GnRHa/dienogest, dienogest/GnRH 
as second treatment and surgery as final option. Subsequent treatments were only 
for patients that did not respond to previous treatment. Discount was not applied 
as costs occurred within 1 year period. Results: The CM model shows that for 
both treatment pathways and perspectives dienogest is a cost-saving alternative. 
Under private payer perspective for 2TS and 3TS: BRL 1020.42 VS BRL 2328.94 and 
BRL 1461.22 VS BRL 2377.52 for dienogest and GnRHa respectively. Under public 
payer perspective for 2TS and 3TS: BRL 882.74 VS BRL 768.13 and BRL 942.18 VS BRL 
856.77 for dienogest and GnRHa respectively. Efficacy for 2TS and 3TS are: 91.58% 
testing/delivering and definition of the CL test threshold. The values obtained were 
LR+ 3,98/LR- 0,33 (FN) and LR+ 2,22/LR- 0,54 (CL). For the whole hypothetical cohort 
the total costs of the FN and CL were 2,3 billion and 890 million, respectively. The 
difference of avoided hospitalizations between the tests was 244 for FN. ICER was 
BRL 5,834,35. ConClusions: Both diagnostic tests are important alternatives for 
the detection of premature birth in Brazil. Studies of prediction of preterm delivery 
using CL have important limitations beyond the fact that CL measure is an operator/
machine dependent procedure. In women with symptomatic preterm labor FN is a 
cost-effective test strategy for prediction of preterm births.
PIH23
Cost-effeCtIveness of vaCCInatIon agaInst HerPes zoster and 
PostHerPetIC neuralgIa: a CrItICal revIew
Kawai K.1, Préaud E.2, Baron-Papillon F.2, Acosta C.J.1
1Merck & Co., Inc, West Point, PA, USA, 2Sanofi Pasteur MSD, Lyon, France
objeCtives: To systematically review cost-effectiveness studies of vaccination 
against herpes zoster (HZ) and post-herpetic neuralgia (PHN). Methods: We 
searched MEDLINE and EMBASE databases for eligible studies until June 2013. We 
extracted information regarding model structure, model input parameters, and 
study results. We compared the results across studies by projecting the health and 
economic impacts of vaccinating 1 million adults over their lifetimes. Results: We 
identified 14 cost-effectiveness studies performed in North America and Europe. 
Results ranged from approximately US$10,000 to US$100,000 per quality-adjusted 
life years gained, though most studies in Europe concluded that zoster vaccination 
is likely to be cost-effective. All studies used similar model structure. Differences 
in results among studies are largely due to differing assumptions regarding dura-
tion of vaccine protection and a loss in quality of life associated with HZ and to 
a larger extent, PHN. In addition, studies found that vaccine efficacy against PHN, 
age at vaccination, and vaccine cost strongly influenced the results in sensitiv-
ity analysis. ConClusions: Our review generally supports the economic value of 
this preventive intervention, particularly in Europe, which will become increasingly 
important as population ages. Future research addressing key model parameters 
and cost-effectiveness studies in other parts of the world are needed.
PIH24
an eConomIC evaluatIon alongsIde a ClInICal trIal (eeaCt) In PelvIC 
floor medICIne
Brennan V.K.1, Dixon S.2, Jones G.2, Radley S.3, Jacques R.2, Wood H.2, Ledger W.4
1RTI Health Solutions, Sheffield, UK, 2University of Sheffield, Sheffield, UK, 3Sheffield Teaching 
Hospitals Charitable Trust, Sheffield, UK, 4University of New South Wales, Sydney, Australia
objeCtives: To determine the cost-effectiveness of using an online questionnaire 
(ePAQ-PF) in combination with a telephone consultation compared to standard 
care. Methods: All women, aged ≥ 18 years and referred to urogynaecology ser-
vices in Sheffield were eligible. Women completed ePAQ-PF online and then received 
a telephone consultation (intervention), or face-to-face consultation (standard 
care). Costs for ePAQ-PF completion and consultation were derived in a microcost-
ing study. Resource use data were collected at 6-months follow-up. The SF-12 was 
administered at baseline and follow-up. SF-6D estimates were used to calculate 
quality-adjusted life-years (QALYs). Patient experience was measured by the Patient 
Experience Questionnaire and Client Satisfaction Questionnaire. Results: A total of 
195 women were randomised. Consultation costs for the intervention group (£31.75) 
were lower than for the control (£72.17). The intervention group incurred greater 
direct costs and personal expenditure during follow-up. However lower costs asso-
ciated with productivity loss for the intervention group resulted in lower indirect 
costs per-patient. Mean total costs per-patient were £38.04 greater in the intervention 
group (£1,139.86) than the control (£1101.82). SF-6D scores reduced slightly during 
follow-up for the intervention group, and increased slightly for the control, resulting 
in QALY loss for the intervention group, and QALY gains for the control. Statistically 
significant gains in patient experience were identified for the intervention group, 
although in strict cost-utility terms the intervention was dominated by the control. 
Incremental costs and QALYs resulted in a negative incremental cost-effectiveness 
ratio (ICER). ConClusions: Although the intervention was not cost-effective com-
pared to the controls, there was a significant difference in an important aspect of the 
care process, which was not captured by the ICER. This highlights the importance of 
decision makers accounting for intervention effects that fall outside the conventional 
conceptualization of the QALY. Methods could be developed that allow non-health 
effects, such as process utility, to be incorporated into the QALY.
PIH25
PHarmaCoeConomIC analysIs of Progestogen PreParatIons for 
tHreatened aBortIon treatment In ukraIne
Tkachova O.1, Iakovlieva L.1, Mishchenko O.1, Matyashova N.2
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Kharkiv, 
Ukraine
objeCtives: Comparative evaluation the cost effectiveness of threatened abor-
tion treatment by two regimens: oxyprogesteronicaproas and dydrogesterone in 
Ukraine. Methods: Pharmacoeconomic analysis was based on the results of com-
parative randomized trial (Belousov Yu. B., Karpov O.I., Ailamazian E.K., 2008). Two 
regimens for threatened abortion treatment: oxyprogesteronicaproas and dydroges-
terone were evaluated. Treatment with dydrogesterone (20 mg per day or 2 tablets 
per day) was carried out during 8 weeks before closure forming placenta (56 days). 
Oxyprogesteronicaproas (250 mg per day) was used from 14 to 20 weeks of gestation 
(42 days). For determining the cost of therapy only the cost of drugs and auxiliary 
materials (syringes, alcohol) for both schemes were taken into account. The prices 
of drugs were taken from the information system “Drugs” of Company “Morion” 
(February, 2013, Ukraine). The currency ratio of UAH to dollar (USA) on 01.02.13 was 
8,12:1. As an indicator of efficacy the number of saved pregnancy after treatment 
was used. Results: The effectiveness of oxyprogesteronicaproas therapy was 
88.6%, and dydrogesterone - 96.3%, the cost of treatment was $ 78.63 and $ 77.96 
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were asked to complete Accept and MMAS-4 questionnaires at Month 1, 3 and 
6 after having given their informed consent. The structure was explored through 
PCA, and confirmed with multi-trait analysis. Internal consistency reliability 
of dimensions was assessed through Cronbach’s alpha. Scale-scale correla-
tions were calculated. Results: After reduction, Accept was made of 25 items 
organised in 1 overall Acceptance score and 6 domain-specific scores (efficacy, 
tolerance, convenience, constraints, treatment duration, multiple medica-
tion). Cronbach’s alpha was 0,85 for overall Acceptance score, which met con-
vergent and divergent validity criteria (both 100%). The domain-specific scores 
showed satisfactory to good results (Cronbach’s alpha ranging from 0,67 - 0,87, 
convegrent validity ranging from 63% to 100%, and divergent validity ranging 
from 33% - 100%). Scale-scale correlations ranged from 0.02 to 0.58, confirming the 
multi-dimensional nature of the questionnaire. The good properties of Accept were 
stable over time. ConClusions: Accept is a brief, comprehensive, generic ques-
tionnaire focused on Acceptance. Initial validation in a population of patients with 
a wide range of long-term treatment showed promising results and confirmed 
the position of Acceptance. Further, disease-specific, large prospective study are 
needed to assess the ability of Accept to predict persistence to treatment.
PIH32
determInants of non-adHerenCe to medICatIons among CHronIC 
PatIents In maCCaBI HealtH Care servICes
Simon Tuval T.1, Triki N.2, Chodick G.2, Greenberg D.1
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Maccabi Healthcare Services, Tel Aviv, 
Israel
objeCtives: Implementation of co-payments may reduce the use of essential medi-
cations, worsen patients’ outcomes, and increase overall health care costs. The aim 
of this study was to examine to what extent non-adherence of chronic patients to 
medication stems from financial reasons and what determinants are associated with 
non-adherence. Methods: A telephone survey was conducted among a representa-
tive sample of Maccabi Healthcare Services chronic patients aged ≥ 55 yrs (n= 522). 
Respondents were defined as non-adherent if they reported they had stopped tak-
ing prescribed medications in the previous year and/or not purchasing prescribed 
medications due to its cost. Additional information collected included: age, gender, 
income, receiving explanation from a physician regarding the therapy, and out-of-
pocket expenditure for prescribed medications. Results: Mean age of the study 
population was 69.9±9.0 yrs (53% were male). Sixteen percent of respondents were 
defined as non-adherent, in 60% of them it was due to medication’s cost. No sig-
nificant differences were found between adherent and non-adherent respondents 
with regard to: age, gender, family status, country of birth, supplementary insurance 
coverage, or education. In a multivariable logistic regression model, non-adherence 
was associated with: lack of physician explanation about prescribed medications 
(OR= 2.88, 95%CI: 1.46-5.68, P= 0.002); higher out-of-pocket expenditure on medications 
(OR= 1.93, 95%CI: 1.04-3.61, P= 0.04), and lower household income (OR= 0.81, 95%CI: 
0.69-0.96, P= 0.01). ConClusions: Information provided by physicians is associated 
with adherence of chronic patients to prescribed medications. Low income and high 
out-of-pocket expenditure for prescribed medication are associated with non-adher-
ence. Since adherence is strongly affected even by a relatively low and flat co-payment 
as applied in Maccabi Healthcare Services, health policy makers may consider adop-
tion of value-based co-payments that are differentiated by treatment value rather 
than by its cost, and targeted mainly at chronic patients. This approach may lead to 
improved adherence and outcomes with the potential of reducing long-term costs.
PIH33
Cost-effeCtIveness of medICatIon adHerenCe enHanCIng 
InterventIons: a systematIC revIew
Oberjé E.1, de Kinderen R.2, Evers S.M.2, de Bruin M.1, van Woerkum C.3
1University of Amsterdam, Amsterdam, The Netherlands, 2Maastricht University, Maastricht, The 
Netherlands, 3Wageningen University, Wageningen, The Netherlands
objeCtives: In light of the presumed costs of non-adherence to medication and the 
pressure to reduce unnecessary health care expenditures in the current economic 
climate, a review that assesses evidence of cost-effectiveness of adherence enhancing 
interventions would be timely. The objective of this paper is to examine the cost-
effectiveness of adherence enhancing interventions and the quality of the studies 
reviewed. Methods: MEDLINE, PsycInfo, EconLit and the Centre for Reviews and 
Dissemination databases were searched for randomised controlled trials that per-
formed full economic evaluations of adherence enhancing interventions. Information 
was collected on study characteristics, cost-effectiveness of treatment alternatives, 
quality of economic evaluations, and risk of bias. Results: Fourteen studies were 
included, of which the overall quality was found to be moderate. Five used a societal 
perspective, eight a provider perspective, and a single study used a patient perspec-
tive. Ten studies examined interventions that were both more costly and more effec-
tive than usual care, and four were less costly and more effective. Comprehensive 
evidence from the societal perspective yielded disappointing results for potential 
cost-effectiveness of adherence interventions. Studies from other perspectives pro-
vided weak to moderately promising evidence that adherence interventions can 
be cost-effective. ConClusions: Few randomised controlled trials examined the 
cost-effectiveness of adherence interventions. There was limited evidence of poten-
tial cost-effectiveness of adherence programmes. Most interventions did not report 
whether their intervention was effective in the first place, and many suffered from 
methodological limitations. To demonstrate that adherence interventions offer soci-
etal benefits, we recommend that the most promising interventions are subjected to 
a rigorous cost-effectiveness evaluation.
PIH34
a systematIC revIew of PatIent PreferenCes for suBCutaneous 
medICatIons
Ridyard C., Dawoud D., Hughes D.A.
Bangor University, Bangor, UK
and 97.87% respectively. ConClusions: This analysis portends dienogest as a cost-
saving alternative for the treatment of EAPP compared to GnRHa in Brazil from the 
public and private payer perspective.
PIH29
InvestIgatIng tHe ImPaCt of mental HealtH status on HealtH and 
soCIal Care Costs of older PeoPle after aCute HosPItal admIssIon
Berdunov V., Franklin M., Tanajewski L., Harwood R., Goldberg S., Gladman J., Elliott R.A.
University of Nottingham, Nottingham, UK
objeCtives: In England, nearly two-thirds of older people in acute hospital care 
suffer from co-morbid physical and mental health conditions. This study inves-
tigated the health and social care costs for a group of older (70+) people iden-
tified with a mental health condition after hospital admission. Methods: The 
Better Mental Health (BMH) study recruited 247 patients at hospital admission in 
Nottingham, England. Electronic administrative records were sought for six months 
post-admission from health (services: general practices, hospitals, ambulance trans-
port, intermediate and mental health care) and social care. The cohort was charac-
terised by one or more aspects of mental health: cognitive impairment, depression, 
delirium, and neuropsychiatric health. Differences in mean cost between groups 
were assessed using t-tests; association between mental health and service-level 
cost was investigated using GLM regression. Results: Health and social care costs 
were derived for all 247 participants, except primary care, derived for 122 (subset) 
participants due to GP recruitment. In the subset, mean (95% CI, median, range) total 
cost was £9842 (8573-11256, 7717, 715-48795). Mean cost (95% CI) for mental health 
care was significantly (p< 0.05) higher for patients: with depression than without 
(£194 (106-322) Vs. £55 (17-111)); bottom-50% on the neuropsychiatric health scale 
(£202 (124-298) Vs. £55 (16-118)). Patients with delirium, compared to without, had 
significantly lower costs for GP consultations (£316 (196-492) Vs. £552 (429-701)) 
and hospital outpatient visits (£333 (253-444) Vs. £497 (400-621)). The GLM did not 
identify a significant association between aspects of mental health and service-
level costs. ConClusions: This study suggests a person’s mental health affects 
consumption of some, but not all, services evaluated. In general, these patients are 
costly, high resource-users, of health and social care services; however, this con-
sumption pattern cannot be attributed to one particular aspect of mental health. 
Future work should investigate the impact of physical and mental health comor-
bidities on resource-use.
IndIvIdual’s HealtH – Patient-reported outcomes & Patient Preference studies
PIH30
medICatIon adHerenCe and adverse HealtH outComes In CommunIty 
dwellIng older PatIents
Cahir C.1, Fahey T.2, Teljeur C.3, Bennett K.4
1Trinity College Dublin, Dublin 8, Ireland, 2Royal College of Surgeons in Ireland, Dublin, Ireland, 
3Health Information and Quality Authority, Dublin, Ireland, 4Trinity Centre for Health Sciences, 
Dublin, Ireland
objeCtives: To determine the association between medication adherence and 
adverse drug events (ADEs), health related quality of life (HRQOL) and hospitalisa-
tion in older community dwelling patients. Methods: A retrospective cohort study 
of 855 patients aged ≥ 70 years from 15 general practices in Ireland in 2010. Medication 
adherence was measured by: (i) the Medication Possession Ratio (MPR) using national 
pharmacy claims dispensing data; and (ii) self-report using the Morisky Medication 
Adherence Scale. ADEs and hospitalisation were measured by patient medical record 
and self-report for the previous 6 months. ADEs were reviewed by two independent 
clinicians. HRQOL was measured using EQ-5D. Multilevel Poisson and linear regression 
were used to examine how the number of ADEs, utility and hospitalisation varied by 
adherence after adjusting for patient and practice level covariates; socioeconomic 
status, deprivation, co-morbidity, number of drugs, functional disabilities, social sup-
port and health insurance. Results: A total of 592 (69%) patients were adherent 
based on dispensed pharmacy claims data (MPR ≥ 80%) and 553 (63%) self-reported 
adherence to their medication. The median MPR for self-reported adherent patients 
was 0.88 (IQR: 0.78, 0.95) compared to 0.86 (IQR: 0.71, 0.93) for non-adherent patients 
(p< 0.01). Non-adherence (MPR< 80%) was not significantly associated with any ADEs 
but self-reported non-adherent patients had an increased risk of any ADEs (IRR 1.18; 
95% CI 1.05, 0, 1.33 p< 0.01). Non-adherent patients had a significantly lower mean 
HRQOL utility (MPR coefficient, -0.11, SE 0.03, p< 0.001; self-report coefficient, -0.06, 
SE 0.01, p< 0.001) and an almost two-fold increased risk in the expected rate of any 
hospitalisation (MPR IRR, 1.75; 95% CI, 1.42, 2.15, p< 0.001; self-report IRR, 1.53; 95% CI, 
1.16, 2.01, p< 0.01) compared to adherent patients. ConClusions: Non-adherence 
was significantly associated with adverse health outcomes. Developing methods 
to assist older adults in accurate and safe management of their medications may 
increase their quality of life.
PIH31
valIdatIon of aCCePt, a new generIC measure to assess How PatIents 
wItH CHronIC dIseases BalanCe Between tHe advantages and 
dIsadvantages of followIng tHe reCommended treatment regImen 
In real-lIfe
Arnould B.1, Gauchoux R.2, Meunier J.1, Gilet H.1, Regnault A.1
1Mapi, Lyon, France, 2Mapi, Real World Evidence, Lyon, France
objeCtives: To reduce, score, and validate the Accept questionnaire. Methods: 
Accept is a 32-items PRO questionnaire measuring the concept of Acceptance. 
It was developed based on grounded theory and qualitative research. Each 
treatment characteristic was assessed on a response scale opposing “easy to 
accept” to “not easy to accept”. We conducted an observational prospective 
study on 182 subjects engaged in long-term treatment regimen. Adult patients 
where consecutively recruited by a network of pharmacists when prescribed 
with a drug indicated in various chronic diseases (including asthma, diabetes, 
various cardio-vascular diseases, retroviral infections, osteoporosis). Patients 
